Label Changes for:
Cancidas (caspofungin acetate) for Injection
October 2010
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
October 2010
ADVERSE REACTIONS
- angioedema
January 2010
WARNINGS AND PRECAUTIONS
Hepatic effects
- ...in healthy volunteers and in adult and pediatric patients...In some adult and pediatric patients...
USE IN SPECIFIC POPULATION
Pediatric Use
- Postmarketing hepatobiliary adverse events have been reported in pediatric patients with serious underlying medical conditions
